StreetAlpha.app
Home › Stocks › INKT

MiNK Therapeutics, Inc. (INKT)

$9.29
▼ −0.16%
LAST CLOSE · NOV 17

MiNK Therapeutics develops iNKT cell therapy candidates for cancers and graft versus host disease, still in clinical trials. It last closed at $9.29 on Nov 17, down 0.16% on the day. The average 12-month price target from 2 analysts is $44.00 (+373.9% from the last close), with a high of $50.00 and a low of $38.00.

AI Auto Pilots
Is INKT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$11.0M
EPS (diluted)
−$2.23
Valuation
Market cap
$47.7M
5.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$7.5M
At Sep 30
Shareholder equity
−$16.3M
Shares outstanding
5.1M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$30.2M−$30.2MFY2021FY2022: −$28.0M−$28.0MFY2022FY2023: −$22.5M−$22.5MFY2023FY2024: −$10.8M−$10.8MFY2024FY2025: −$12.5M−$12.5MFY2025

From INKT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated INKT in the past 90 days, not enough for a consensus
Average 12-month target
$44.00
▲ 373.9% upside

Based on 2 analysts who set a price target on INKT in the past 90 days. The average target is $44.00, with a high of $50.00 and a low of $38.00, compared with the last close of $9.29.

Low $38.00Avg $44.00High $50.00
Blue marker: last close $9.29
Highest target$50.00
Average target$44.00
Lowest target$38.00
Latest rating changes
HC Wainwright & Co.Assumed coverage
Nov 4Buy$38
B. Riley SecuritiesReiterated
Oct 21Buy$50
DateFirmActionRatingPrice target
Nov 4HC Wainwright & Co.Assumed coverageBuy$38
Oct 21B. Riley SecuritiesReiteratedBuy$50
Loading…

Technical Analysis

INKT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 10% below its 20 day and 18% below its 50 day average. It is 20% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot at $9.27, and the nearest resistance the Pivot R1 at $9.32.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.5%/day
Key levels
$16.9352 week high+82.2%
$11.25Swing high (Jul 27)+21.1%
$11.16200 day average+20.1%
$11.08100 day average+19.3%
$11.0050 day average+18.4%
$10.2520 day average+10.3%
$9.32Pivot R1+0.3%
$9.29Last close
$9.27Pivot−0.2%
$9.23Pivot S1−0.6%
$9.19Swing low (Oct 20)−1.1%
$8.4852 week low−8.7%
Indicators
RSI (14)37.75Weak, oversold below 30Neutral
MACD-0.41Below its signal lineBearish
Stochastic9.2Near the bottom of its rangeOversold
ADX (14)17.7No clear trend
Williams %R-87.4Oversold below −80, overbought above −20Oversold
CCI (20)-161.6Oversold below −100, overbought above 100Oversold
Rate of change−13.9%Change over 10 sessionsBearish
ATR (14)$0.69Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for INKT

What happened before

See how INKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow INKT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How INKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in INKT in the last 90 days.

Loading…

See today’s whale options flow across the market →

INKT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼6 buying vs 10 selling
  • ●Held by funds -0.5 pts
  • ▼Funds holding -3
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2629−10.3%
In funds' top 1000–
Held by funds3.8%4.2%−0.5 pts
New / increased1 / 58 / 6−57.1%
Reduced / sold out6 / 43 / 3+66.7%
Put/call ratio–––
SuperinvestorsKen GriffinSold out
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INKT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INKT is in one of them and how their past INKT trades turned out.

INKT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INKT in an article yet. Here's the latest on the wider market.

About MiNK Therapeutics

MiNK Therapeutics is a biotechnology company based in New York that develops cell therapies built on its iNKT cell platform. Its product candidates are still being tested in clinical trials and have not been approved for sale. The treatments are being studied for conditions such as graft versus host disease, solid tumors and multiple myeloma, and the company's intended customers are patients and the physicians who treat them. It competes with other cell therapy developers and with existing and newer treatments.

Headquarters
New York, NY